Prosecution Insights
Last updated: November 12, 2026
Application No. 18/894,723

METHODS, DEVICES, AND COMPOSITIONS FOR TREATING VASCULAR ANEURYSMS

Non-Final OA §102§103§DP
Filed
Sep 24, 2024
Priority
Mar 15, 2015 — provisional 62/133,450 +2 more
Examiner
DAVID, SHAUN L
Art Unit
3771
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Board Of Trustees Of The Leland Stanford Junior University
OA Round
1 (Non-Final)
73%
Grant Probability
Favorable
1-2
OA Rounds
91%
With Interview

Examiner Intelligence

Grants 73% — above average
73%
Career Allowance Rate
436 granted / 599 resolved
+2.8% vs TC avg
Strong +18% interview lift
Without
With
+18.4%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
32 currently pending
Career history
639
Total Applications
across all art units

Office Action

§102 §103 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Specification The specification is objected to as failing to provide proper antecedent basis for the claimed subject matter. See 37 CFR 1.75(d)(1) and MPEP § 608.01(o). Correction of the following is required: pulsatile wall motion is not mentioned in the specification. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claim(s) 1-5 and 7-12 is/are rejected under 35 U.S.C. 102(a)(1) as being anticipated by US 6,093,199 to Brown (hereinafter “Brown”), as evidenced by “Pulsatile Wall Motion (PWM) Measurements after Endovascular Abdominal Aortic Aneurysm Exclusion are not Useful in the Classification of Endoleak” by Lindblad et al. (hereinafter “Lindblad”) and “Reduced Pulsatile Wall Motion of Abdominal Aortic Aneurysms after Endovascular Repair” by Malina et al. (hereinafter “Malina”). Regarding claim 1, Brown discloses (see abstract; Figs. 1-8; and Col. 4, line 33 - Col. 12, line 31) a method of treating a vascular aneurysm in an artery (see Col. 7, line 61 - Col. 8, line 6), the method comprising positioning a support (30) along at least a portion of at least one vascular segment adjacent to the vascular aneurysm (see Fig. 8 and Col. 5, lines 48-59) to reduce pulsatile wall motion of the artery (see Col. 5, lines 18-63 and Col. 7, line 61 - Col. 8 line 21, the device is used to provide an endovascular repair of the aneurysm such that the aneurysm is isolated from blood flow by endografting - as evidenced by both Lindblad and Malina in their abstract's conclusion sections and in their papers as a whole, endografting an aneurysm inherently results in reduced pulsatile wall motion, therefore, Brown's method would inherently result in reduced pulsatile wall motion of the artery since it is treating the aneurysm with endografting to isolate the aneurysm from blood flow). Brown further discloses (claims 2-5 and 8-9) wherein the reduced pulsatile wall motion of the artery causes reduced axially tethering forces on the vascular aneurysm; wherein the reduced pulsatile wall motion causes reduced axial stress on the vascular aneurysm; wherein the reduced pulsatile wall motion of the at least one vascular segment causes a reduced stiffness gradient towards the vascular aneurysm; and wherein the reduced pulsatile wall motion causes reduced cyclic strain of the vascular aneurysm; wherein growth of the vascular aneurysm following the reduced pulsatile wall motion of the artery is reduced relative to growth of the vascular aneurysm in the absence of the reduced pulsatile wall motion of the artery; wherein inflammation in the artery following the reduced pulsatile wall motion of the artery is reduced relative to inflammation in the artery in the absence of the reduced segmental stiffening of the artery (see Col. 5, lines 18-63 and Col. 7, line 61 - Col. 8 line 21, and as discussed above, there is inherent reduced pulsatile wall motion of the artery - the claim language establishes that reduced pulsatile wall motion results in reduced axially tethering forces and axial stress of the vascular aneurysm, a reduced stiffness gradient, a reduced cyclic strain; reduced growth after treatment; and reduced inflammation are inherent results of treating the aneurysm - it has been held that newly discovered results of known processes directed to the same purpose are not patentable because such results are inherent, see In re May, 574 F.2d 1082, 1090, 197 USPQ 601, 607 (CCPA 1978), accordingly, since Brown discloses the same method steps as claimed directed to the same purpose of treating an aneurysm, the recognition of newly discovered results as a result of the reduced pulsatile wall motion (reduced axially tethering forces, reduced axial stress, reduced stiffness, reduced cyclic strain, reduced growth, and reduced inflammation) would not constitute patentable subject matter because such results are inherent); (claim 7) wherein the positioning the support comprises implanting an intravascular stent at the at least one vascular segment (see Fig. 8 and Col. 11, lines 16-28); (claim 10) wherein the at least one vascular segment comprises a vascular segment upstream of the vascular aneurysm or a vascular segment downstream of the vascular aneurysm (see Fig. 8); (claim 11) wherein the at least one vascular segment comprises a vascular segment upstream of the vascular aneurysm and a vascular segment downstream of the vascular aneurysm (see Fig. 8); (claim 12) wherein the support is a physical structure applied within or outside of the at least one vascular segment (see Fig. 8). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 6 is/are rejected under 35 U.S.C. 103 as being unpatentable over Brown in view of US 2010/0241214 A1 to Holzer et al. (hereinafter “Holzer”). Brown discloses the invention substantially as set forth above but fails to specifically disclose, with respect to claim 6, wherein the positioning the support comprises applying a surgical adhesive to the at least one vascular segment. Holzer discloses, in the same field of endeavor, the known use of applying a surgical adhesive to at least one vascular segment to position a support (porous structure 104) for the purpose of delivering an adhesive so that the porous structure can be securely adhered to the lumen wall (see [0226]). It would have been obvious to one having ordinary skill in the art before the effective filing date of the claimed invention to have modified Brown's support 30 with the adhesive taught by Holzer in order to deliver an adhesive so the support can be securely adhered to the lumen wall. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 13-19 and 20-22 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 10, 11, 16 and 18-20 of U.S. Patent No. 10,779,964. Although the claims at issue are not identical, they are not patentably distinct from each other because the current claims only differ by using the limitation “selectively reducing cyclic strain” instead of “increasing the mechanical stiffness”, but as set forth below, the specification of ‘964 establishes that these are inversely proportional to each other and thus increasing the mechanical stiffness from the ‘964 claims would correlate to a reduction in cyclic strain” in the current claims. Regarding claim 13, '964 claim 10 recites a method of minimizing growth of a vascular aneurysm in an artery (Col. 22, lines 20-21), the method comprising selectively reducing cyclic strain (see Col. 11, lines 29-30, looking at the spec. to determine the definition of cyclic strain as used in the claims, the spec. makes clear that mechanical stiffening is equivalent to reduced cyclic strain) of at least one vascular segment adjacent to the vascular aneurysm such that the vascular aneurysm is not directly treated (Col. 22, lines 21-25). Regarding claim 20, '964 claim 18 recites a method of treating a vascular aneurysm (C22L46), the method comprising reducing cyclic strain (see Col. 11, lines 29-30, looking at the spec. to determine the definition of cyclic strain as used in the claims, the spec. makes clear that mechanical stiffening is equivalent to reduced cyclic strain) on at least one aneurysm-adjacent vascular segment by positioning a stiffening device or stiffening composition at the at least one aneurysm-adjacent vascular segment and not at the vascular aneurysm (C22L46-52) Regarding the dependent claims, there is correspondence as follows (noting that for claims 14 and 16, because the claims recite that reducing the cyclic strain results in the claimed inherent characteristics, then the claims of ‘964 would also result in those inherent characteristics). Current claim # 14 15 16 17 18 19 21 22 '964 claim # 10 10 10 11 10 16 19 20 Claims 13-19 and 20-22 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 13-14, 19-20, and 23-24 of U.S. Patent No. 12,097,135. Although the claims at issue are not identical, they are not patentably distinct from each other because the current claims only differ by using the limitation “selectively reducing cyclic strain” instead of “increasing the mechanical stiffness”, but as set forth below, the specification of ‘135 establishes that these are inversely proportional to each other and thus increasing the mechanical stiffness from the ‘135 claims would correlate to a reduction in cyclic strain” in the current claims. Regarding claim 13, '135 claim 13 recites a method of minimizing growth of a vascular aneurysm in an artery (Col. 22, lines 45-46), the method comprising selectively reducing cyclic strain (see Col. 11, lines 31-32, looking at the spec. to determine the definition of cyclic strain as used in the claims, the spec. makes clear that mechanical stiffening is equivalent to reduced cyclic strain) of at least one vascular segment adjacent to the vascular aneurysm such that the vascular aneurysm is not directly treated (Col. 22, lines 45-49). Regarding claim 20, '135 claim 23 recites a method of treating a vascular aneurysm (C23L18), the method comprising reducing cyclic strain (see Col. 11, lines 29-30, looking at the spec. to determine the definition of cyclic strain as used in the claims, the spec. makes clear that mechanical stiffening is equivalent to reduced cyclic strain) on at least one aneurysm-adjacent vascular segment by positioning a stiffening device or stiffening composition at the at least one aneurysm-adjacent vascular segment and not at the vascular aneurysm (C23L18-C24L4)). Regarding the dependent claims, there is correspondence as follows (noting that for claims 14 and 16, because the claims recite that reducing the cyclic strain results in the claimed inherent characteristics, then the claims of ‘135 would also result in those inherent characteristics). Current claim # 14 15 16 17 18 19 21 22 '135 claim # 13 13 13 14 20 19 23 224 Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SHAUN L DAVID whose telephone number is (571)270-5263. The examiner can normally be reached M-F 10AM-6:30PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Darwin Erezo can be reached at 571-272-4695. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SHAUN L DAVID/ Primary Examiner, Art Unit 3771
Read full office action

Prosecution Timeline

Sep 24, 2024
Application Filed
Jun 15, 2026
Response after Non-Final Action
Aug 10, 2026
Non-Final Rejection mailed — §102, §103, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12788391
KNOTLESS SUTURE SHUTTLING AND ANCHORING SYSTEM
3y 4m to grant Granted Nov 10, 2026
Patent 12788955
Electrical Disconnect for Tattoo Machine
1y 11m to grant Granted Nov 10, 2026
Patent 12778588
APPARATUS AND METHOD FOR ENDOSCOPIC ANASTOMOSIS OF THE STOMACH AND THE BOWEL
3y 1m to grant Granted Nov 03, 2026
Patent 12773203
SURGICAL CONSTRUCTS AND METHODS OF TISSUE REPAIR
2y 11m to grant Granted Oct 27, 2026
Patent 12758208
SUTURE BUTTON AND METHODS
2y 8m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
73%
Grant Probability
91%
With Interview (+18.4%)
Low
PTA Risk
Based on 599 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month